Skip to main content

Herpes Simplex Virus Type I Stromal Keratitis

1
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BDgene Therapeutics
BDgene TherapeuticsChina - Shanghai
1 program
1
BD111Phase 23 trials
Active Trials
NCT06474442Recruiting40Est. Mar 2027
NCT06474416Active Not Recruiting16Est. Mar 2026
NCT04560790Completed3Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BDgene TherapeuticsBD111
BDgene TherapeuticsBD111
BDgene TherapeuticsBD111

Clinical Trials (3)

Total enrollment: 59 patients across 3 trials

A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

Start: Apr 2025Est. completion: Mar 202740 patients
Phase 2Recruiting

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

Start: Sep 2023Est. completion: Mar 202616 patients
Phase 1Active Not Recruiting

Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

Start: Nov 2020Est. completion: Jul 20223 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 59 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.